Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The favorable effects of high levels of fetal hemoglobin (Hb F) in sickle cell disease have been recognized for several decades. This has been an important incentive for the development of therapeutic agents that increase Hb F production. 5-Azacytidine, the first such agent in clinical use, was proposed based on a molecular understanding of the role of DNA methylation in globin gene regulation. Controversy over the mechanism of Hb F induction by 5-azacytidine led to the identification of hydroxyurea as another agent that can increase Hb F production. Although the clinical benefit of hydroxyurea has been demonstrated in a randomized clinical trial, greater increases in Hb F are clearly needed for optimal therapeutic effect. Butyrates also increase Hb F levels, and their use in combination with hydroxyurea appears to be synergistic. Now that multiple therapeutic agents are available for Hb F induction, the use of combination therapy to increase Hb F levels sufficiently to prevent all the complications of sickle cell disease has become a realistic goal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression
Heinzel, T., Lavinsky, R. M., Mullen, T.-M., Söderström, M., Laherty, C. D., Torchia, J., Yang, W.-M., Brard, G., Ngo, S. D., Davie, J. R., et al. (1997) · Nature · doi:10.1038/387043a0 · Cited by 1,214
Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression
Laherty, C. D., Yang, W.-M., Sun, J.-M., Davie, J. R., Seto, E., & Eisenman, R. N. (1997) · Cell · doi:10.1016/s0092-8674(00)80215-9 · Cited by 938
Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia.
Platt, O. S., Orkin, S. H., Dover, G., Beardsley, G. P., Miller, B., & Nathan, D. G. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111464 · Cited by 535
A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the β-Globin Disorders
Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-P., Vichinsky, E. P., & Olivieri, N. F. (1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280202 · Cited by 437
Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice
Kaul, D. K., & Hebbel, R. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9225 · Cited by 417
Kinney, T. R., Helms, R. W., O’Branski, E. E., Ohene‐Frempong, K., Wang, W. C., Daeschner, C., Vichinsky, E. P., Redding‐Lallinger, R., Gee, B. E., Platt, O. S., et al. (1999) · PubMed · Cited by 417
Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407
Research works printed but not linked: 7
- Steinberg, 2000, Blood, 96, 485a
- Sutton, 1999, Blood, 94, 416a
- Fruchtman, 1997, Semin Hematol, 34, 17
- Kinney, 1999, Blood, 94, 1550
- Atweh, 1999, Blood, 93, 1790
- Sutton, 1998, Blood, 92, 694a
- Steinberg, 1999, Blood, 94, 644a
Cited by
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Alternative splicing in disease and therapy
Garcia-Blanco, M. A., Baraniak, A. P., & Lasda, E. L. (2004) · Nature Biotechnology · doi:10.1038/nbt964 · Cited by 527
Hemoglobin research and the origins of molecular medicine
Schechter, A. N. (2008) · Blood · doi:10.1182/blood-2008-04-078188 · Cited by 381
Self-citationČokić, V. P., Smith, R. D., Beleslin‐Čokić, B. B., Njoroge, J. M., Miller, J. L., Gladwin, M. T., & Schechter, A. N. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16672 · Cited by 375
Self-citation
Metadata
- Authors
- Atweh, G. F., & Schechter, A. N.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Atweh, George F.
- Venue
- Current Opinion in Hematology
- Published
- 2001-03
- Volume
- 8
- Issue
- 2
- Pages
- 123-130
- ISSN
- 1065-6251 (ISSN-L)
- OpenAlex
- W2108041597
- Cited by
- 66
- References
- 42
- Citations by year
- 2025: 1 · 2024: 3 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 2 · 2013: 2 · 2012: 1
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- sickle cell disease, fetal hemoglobin induction, azacitidine, hydroxyurea, butyrate, DNA methylation, globin gene regulation, combination therapy, drug synergy
- MeSH terms
- Decitabine, Anemia, Sickle Cell, Azacitidine, Butyrates, Fetal Hemoglobin, Humans, Hydroxyurea
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. https://app.cochat.ai/papers/10.1097/00062752-200103000-00010
- The paper
- Atweh, G. F., & Schechter, A. N. (2001). Pharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Current Opinion in Hematology. https://doi.org/10.1097/00062752-200103000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.